Related Experiment Videos
Defective class II transactivator expression in a B lymphoma cell line
T Prod'homme1, B Drénou, C De Ruyffelaere
1INSERM U396, Centre de Recherches Biomédicales des Cordeliers, Paris, France.
Leukemia
|February 20, 2004
Summary
Defective MHC class II expression in B-cell lymphoma is linked to reduced tumor-infiltrating lymphocytes. This study identifies a transcriptional defect in MHC2TA (CIITA) as the cause in Rec-1 cells.
Area of Science:
- Immunology
- Molecular Biology
- Oncology
Background:
- Loss of MHC class II expression in B-cell lymphoma correlates with increased tumorigenicity due to fewer tumor-infiltrating lymphocytes.
- Understanding the molecular basis of defective MHC class II expression is crucial for B-cell lymphoma treatment.
Observation:
- The Rec-1 B-cell lymphoma cell line exhibits altered HLA-D gene transcription, similar to cell lines from MHC class II deficiency patients.
- Genetic complementation revealed that Rec-1 cells have a defect in the MHC2TA gene, which encodes the class II transactivator (CIITA).
Findings:
- No mutations were found in the coding sequence of the Rec-1 CIITA transcript.
- A significant reduction in CIITA protein expression was observed in Rec-1 cells, stemming from a transcriptional defect in MHC2TA expression.
- This defect leads to diminished MHC class II expression on lymphoma cells.
Implications:
- The findings highlight a transcriptional defect in MHC2TA (CIITA) as a mechanism for reduced MHC class II expression in B-cell lymphoma.
- Monitoring for variants with reduced CIITA and HLA-DR expression is essential during anti-HLA-DR monoclonal antibody immunotherapy for B-cell lymphomas.